Cellular therapies for heart disease: unveiling the ethical and public policy challenges.
Cellular therapies for heart disease: unveiling the ethical and public policy challenges.
复制标题
心脏病的细胞疗法：揭示伦理和公共政策挑战。
DOI：
10.1016/j.yjmcc.2007.11.005
复制
发表时间：
2008
影响因子：
5
通讯作者：
Hogle,LindaF
中科院分区：
文献类型：
--
作者：
Raval,AmishN;Kamp,TimothyJ;Hogle,LindaF
细胞疗法已成为心血管疾病的潜在革命性治疗方法。有希望的临床前结果导致了一系列基础研究活动，并在全球范围内催生了多项临床试验。然而，尚未确定目标患者群体的最佳细胞类型和递送模式。也没有明确定义细胞干预范围的受益机制。迄今为止的经验已经揭示了无数的伦理和公共政策挑战，这些挑战将影响研究人员和临床医生为基础和临床研究做出决策的方式。从胚胎中提取的干细胞是伦理和政治辩论的前沿，提出了哪些衍生方法在道德和社会上是允许追求的问题，以及哪些方法在技术上是可行的。成体干细胞争议较少;然而，在确定研究设计、细胞处理、递送模式和目标患者群体方面存在重要挑战。成功商业化的途径以及因此广泛获得心脏病细胞疗法的途径才刚刚开始探索。需要基础研究人员、临床医生、监管官员和政策制定者参与的全面、多学科和协作网络，以共享信息，制定研究、监管和政策标准，并实现合理和道德的细胞治疗方法。
Cellular therapies have emerged as a potential revolutionary treatment for cardiovascular disease. Promising preclinical results have resulted in a flurry of basic research activity and spawned multiple clinical trials worldwide. However, the optimal cell type and delivery mode have not been determined for target patient populations. Nor have the mechanisms of benefit for the range of cellular interventions been clearly defined. Experiences to date have unveiled a myriad of ethical and public policy challenges which will affect the way researchers and clinicians make decisions for both basic and clinical research. Stem cells derived from embryos are at the forefront of the ethical and political debate, raising issues of which derivation methods are morally and socially permissible to pursue, as much as which are technically feasible. Adult stem cells are less controversial; however, important challenges exist in determining study design, cell processing, delivery mode, and target patient population. Pathways to successful commercialization and hence broad accessibility of cellular therapies for heart disease are only beginning to be explored. Comprehensive, multi-disciplinary and collaborative networks involving basic researchers, clinicians, regulatory officials and policymakers are required to share information, develop research, regulatory and policy standards and enable rational and ethical cell-based treatment approaches.
登录
查看更多内容
心肌细胞治疗处于十字路口
DOI：
10.1038/ncpcardio0743
发表时间：
2007
期刊：
Nature Clinical Practice Cardiovascular Medicine
影响因子：
--
作者：
B. Nadal;V. Fuster
通讯作者：
V. Fuster
干细胞研究中改变核移植——一个有缺陷的提议。
DOI：
10.1056/nejmp048348
发表时间：
2004
期刊：
The New England journal of medicine
影响因子：
--
作者：
D. Melton;G. Daley;C. Jennings
通讯作者：
C. Jennings
影响因子：
64.5
作者：
Takahashi, Kazutoshi;Yamanaka, Shinya
通讯作者：
Yamanaka, Shinya
影响因子：
64.8
作者：
Chung, Y;Klimanskaya, I;Lanza, R
通讯作者：
Lanza, R
影响因子：
46.9
作者：
J. Moreno;R. Hynes
通讯作者：
R. Hynes